JPWO2021055342A5 - - Google Patents

Download PDF

Info

Publication number
JPWO2021055342A5
JPWO2021055342A5 JP2022517139A JP2022517139A JPWO2021055342A5 JP WO2021055342 A5 JPWO2021055342 A5 JP WO2021055342A5 JP 2022517139 A JP2022517139 A JP 2022517139A JP 2022517139 A JP2022517139 A JP 2022517139A JP WO2021055342 A5 JPWO2021055342 A5 JP WO2021055342A5
Authority
JP
Japan
Prior art keywords
seq
compound
domain
pharmaceutical composition
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022517139A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022548145A5 (https=
JP7773152B2 (ja
JP2022548145A (ja
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/050851 external-priority patent/WO2021055342A1/en
Publication of JP2022548145A publication Critical patent/JP2022548145A/ja
Publication of JP2022548145A5 publication Critical patent/JP2022548145A5/ja
Publication of JPWO2021055342A5 publication Critical patent/JPWO2021055342A5/ja
Priority to JP2025182211A priority Critical patent/JP2026021424A/ja
Application granted granted Critical
Publication of JP7773152B2 publication Critical patent/JP7773152B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022517139A 2019-09-16 2020-09-15 免疫療法の化合物および方法 Active JP7773152B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025182211A JP2026021424A (ja) 2019-09-16 2025-10-29 免疫療法の化合物および方法

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962901198P 2019-09-16 2019-09-16
US62/901,198 2019-09-16
PCT/US2020/050851 WO2021055342A1 (en) 2019-09-16 2020-09-15 Immunotherapy compounds and methods

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025182211A Division JP2026021424A (ja) 2019-09-16 2025-10-29 免疫療法の化合物および方法

Publications (4)

Publication Number Publication Date
JP2022548145A JP2022548145A (ja) 2022-11-16
JP2022548145A5 JP2022548145A5 (https=) 2023-09-21
JPWO2021055342A5 true JPWO2021055342A5 (https=) 2023-09-21
JP7773152B2 JP7773152B2 (ja) 2025-11-19

Family

ID=74883667

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2022517139A Active JP7773152B2 (ja) 2019-09-16 2020-09-15 免疫療法の化合物および方法
JP2025182211A Pending JP2026021424A (ja) 2019-09-16 2025-10-29 免疫療法の化合物および方法

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025182211A Pending JP2026021424A (ja) 2019-09-16 2025-10-29 免疫療法の化合物および方法

Country Status (10)

Country Link
US (1) US20220324972A1 (https=)
EP (1) EP4031565A4 (https=)
JP (2) JP7773152B2 (https=)
KR (1) KR20220087441A (https=)
CN (1) CN115023435B (https=)
AU (1) AU2020350524A1 (https=)
BR (1) BR112022004712A2 (https=)
CA (1) CA3154158A1 (https=)
IL (1) IL291343A (https=)
WO (1) WO2021055342A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20200291130A1 (en) * 2017-03-31 2020-09-17 Merus N.V. Antibodies for the treatment of erbb-2/erbb-3 positive tumors
WO2023043958A1 (en) * 2021-09-16 2023-03-23 Gt Biopharma, Inc. Pd-l1 targeting fusion proteins and methods of use thereof
WO2025136820A1 (en) * 2023-12-18 2025-06-26 Regents Of The University Of Minnesota Poly-antigen cytokine-receptor complexes (paccs), compositions, and methods of use

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140072581A1 (en) * 2012-07-23 2014-03-13 Zymeworks Inc. Immunoglobulin Constructs Comprising Selective Pairing of the Light and Heavy Chains
US20150125386A1 (en) * 2013-11-05 2015-05-07 Immunomedics, Inc. Humanized anti-ceacam5 antibody and uses thereof
WO2015095412A1 (en) * 2013-12-19 2015-06-25 Zhong Wang Bispecific antibody with two single-domain antigen-binding fragments
CA3151221C (en) * 2014-06-30 2026-01-13 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
WO2017008169A1 (en) 2015-07-15 2017-01-19 Zymeworks Inc. Drug-conjugated bi-specific antigen-binding constructs
MX389194B (es) * 2015-10-06 2025-03-20 Univ Minnesota Compuestos terapéuticos y métodos.
WO2017165464A1 (en) * 2016-03-21 2017-09-28 Elstar Therapeutics, Inc. Multispecific and multifunctional molecules and uses thereof
WO2019035938A1 (en) * 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. MULTISPECIFIC MOLECULES BINDING TO BCMA AND USES THEREOF

Similar Documents

Publication Publication Date Title
US20230279101A1 (en) Vegf/dll4 binding agents and uses thereof
JP7308041B2 (ja) 多重特異性抗原結合分子およびその使用
EP3319994B1 (en) Multispecific antigen-binding molecules and uses thereof
AU782994C (en) Treatment of refractory human tumors with epidermal growth factor receptor antagonists
Groner et al. Therapeutic antibodies
PE20231067A1 (es) Anticuerpos y proteinas de fusion que se unen a ccr8 y usos de estos
RU2018116565A (ru) Терапевтические соединения и способы
JP2021510736A5 (https=)
JP2020533311A5 (ja) ＮＫＧ２Ｄ、ＣＤ１６およびＮｅｃｔｉｎ４に結合するタンパク質
RU2012137503A (ru) Лекарственный препарат для лечения и/или профилактики рака
CN104768579A (zh) 使用Wnt途径结合剂来治疗神经内分泌肿瘤的方法
JP2006500009A5 (https=)
CN112679609B (zh) 抗CD16a抗原VHH及相关双特性纳米抗体
US20200095339A1 (en) Novel recombinant bi-functional fusion protein, preparation method therefor and use thereof
TW201712040A (zh) 雙功能抗體用於修飾聚乙二醇化物質之用途
JP2024505556A (ja) がん、腫瘍および腫瘍細胞の局所および全身処置のための方法
JP2018512402A5 (https=)
JPWO2021055342A5 (https=)
JPWO2020081841A5 (https=)
WO2021182571A1 (ja) 癌の治療及び／又は予防のための医薬品
JPWO2022256559A5 (https=)
RU2021113936A (ru) Вовлекающие nk молекулы и способы их применения
Wu et al. Trastuzumab therapies in human epidermal growth factor receptor 2 cancer
KR101927732B1 (ko) ＥｒｂＢ3에 특이적으로 결합하는 항체를 포함하는 항암제 내성 암의 예방 또는 치료용 약학적 조성물 및 이를 이용한 방법
JPWO2020247440A5 (https=)